GE Capital Healthcare Financial Services has announced today that it is providing $7.5 million in financing to Trimel Pharmaceuticals for Phase 2 and 3 clinical development of several OINDPs. Trimel’s pipeline includes asthma and allergic rhinitis therapies based on its Trivair dry powder inhaler technology and male and female sexual dysfunction therapies based on its intranasal gel technology.
Trimel CFO Kenneth Howling commented, “The financing provided by GE Capital is important to our organization because it supports our ability to develop and test innovative new products. GE Capital understands the unique dynamics of our industry and worked closely with us to structure a financing solution to meet our needs.”
Read the GE Capital press release.
